Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma

Table 1

Thalidomide trials in the post-ASCT setting.

Study (authors)		Maintenance phase study arms	EFS	PFS	OS
IFM 99-02; (Attal et al.) AM [33]	597	A: no maintenance; B: pamidronate; C: pamidronate/thalidomide (400 mg/d)	A: 36%; B: 37%; C: 52%; ()		A: 77%; B: 74%; C: 87%; ()
TT-2^*; (Barlogie et al.) AM [34]	668	A: thalidomide 100 mg/d × 1 year 50 mg/d until PD; B: no maintenance	A: 6 years; B: 4.1 years; (		A: 57%; B: 44%; ()
HOVON-50; (Lokhorst et al.) AM [35]	556	A: VAD induction IFN- maintenance; B: TAD induction thalidomide maintenance	A: 22 months; B: 34 months; ()	A: 25 months; B: 35 months ()	A: 60 months; B: 73 months; ()
MRC myeloma IX; intensive group; (Morgan et al.) AM [15]	493	A: thalidomide (50–100 mg/d); B: no maintenance	A: 30 months; B: 27 months; ()		A: 75 months; B: 80 months; ()
BMT CTN-0102; (Krishnan et al.) AM [16]	436	A: dexamethasone/thalidomide (200 mg/d); B: no maintenance		A: 49%; B: 43%; ()	A: 80%; B: 81%; ()
(Maiolino et al.) AM [36]	108	A: dexamethasone/thalidomide (200 mg/d); B: dexamethasone		A: 64%; B: 30%; ()	A: 85%; B: 70%; ( = 0.27)
ALLG MM-6; (Spencer et al.) AM [37]	269	A: prednisolone/thalidomide 100–200 mg/d × 12 months; B: prednisolone		A: 42%; B: 23%; ()	A: 86%; B: 75%; ( = 0.004)
NCIC CTG MY10; (Stewart et al.) AM [38]	332	A: prednisone/thalidomide (200 mg/d); B: no maintenance		A: 28 months; B: 17 months; ()	A: 68%; B: 60%; ()

Both arms in TT-2 received the same 4 induction cycles followed by double ASCT and 4 cycles of consolidation (Figure 6). Thalidomide was given in arm A at a dose of 400 mg/d during induction, 100 mg/d during ASCT, and 200 mg/d during consolidation.